Zobrazeno 1 - 10
of 305
pro vyhledávání: '"Lori Muffly"'
Autor:
Christa L. Meyer, Theresa H.M. Keegan, Ann Brunson, Jeffery J. Auletta, Lindsay M. Morton, Ted Wun, Sara J. Schonfeld, Bryan Valcarcel, Renata Abrahão, Rafeek A. Yusuf, Lori Muffly
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Acute myeloid leukemia (AML) often requires allogeneic hematopoietic cell transplantation (alloHCT) for cure, but historically alloHCT has been strikingly underutilized. Reasons for this remain uncertain at the population level. We examined alloHCT u
Externí odkaz:
https://doaj.org/article/e33668d5cdff463bbbcb0271deca39e6
Autor:
Crystal Mackall, Holden T Maecker, Lekha Mikkilineni, Melody Smith, Saurabh Dahiya, Bita Sahaf, David Miklos, Sally Arai, Surbhi Sidana, Wen-Kai Weng, Dasom Lee, Anmol Goyal, Sushma Bharadwaj, Eric Lau, Mark P Hamilton, Hrishi Srinagesh, Alexandria Jensen, Jayasindhu Mallampet, Sarah Elkordy, Shriya Syal, Sunita Patil, Theresa Latchford, Laura J Johnston, Robert Lowsky, Robert Negrin, Andrew R Rezvani, Judith Shizuru, Everett H Meyer, Parveen Shiraz, Lori Muffly, Matthew J Frank
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Background Fludarabine in combination with cyclophosphamide (FC) is the standard lymphodepletion regimen for CAR T-cell therapy (CAR T). A national fludarabine shortage in 2022 necessitated the exploration of alternative regimens with many centers em
Externí odkaz:
https://doaj.org/article/4eeab2b9098d4e108c29937f804ef916
Autor:
Matthew J. Frank, John Baird, Anne Kramer, Shabnum Patel, Bita Sahaf, Juliana Craig, Emma Crawford, Sheren Younes, Jean Oak, Yasodha Natkunan, Jay Spiegel, Zachary Ehlinger, Harshini Chinnasamy, Warren Reynolds, Hrishi Srinagesh, Yi-Jiun Su, Emily Egeler, Steven Feldman, Crystal Mackall, Lori Muffly, David Miklos
Publikováno v:
HemaSphere, Vol 7, p e3362169 (2023)
Externí odkaz:
https://doaj.org/article/f37aa0e9cdbc48e78c6c20ac96a00324
Autor:
Amanda Cashen, Ashkan Emadi, Edward Abadir, Monzr Al Malki, Peter Tan, Joshua Zeidner, Natasha Edwin, Peter Sayre, Lori Muffly, John Muth, Kenneth Jacobs, Ouiam Bakkacha, Eileen Mcnulty, Angela Pannunzio, Jan Davidson-Moncada
Publikováno v:
HemaSphere, Vol 7, p e98802fe (2023)
Externí odkaz:
https://doaj.org/article/46c7c81f47e14d98be312ef6f8cd9866
Publikováno v:
Haematologica, Vol 107, Iss 12 (2022)
Measurable residual disease (MRD) is the most powerful independent predictor of risk of relapse and long-term survival in adults and children with acute lymphoblastic leukemia (ALL). For almost all patients with ALL there is a reliable method to eval
Externí odkaz:
https://doaj.org/article/94e903ffbdfd492b940d5063f2103239
Autor:
Sammita Satyanarayan, Jay Spiegel, Dominic Hovsepian, Matthew Markert, Reena Thomas, Lori Muffly, David Miklos, Kevin Graber, Brian J. Scott
Publikováno v:
The Neurohospitalist. 13(1)
Background and Purpose Immune Cell Effector Associated Neurotoxicity Syndrome (ICANS) is common amongst patients receiving CD19 targeted Chimeric Antigen Receptor T-cell (CAR-T) therapy. The purpose of this study is to characterize the incidence of s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2daa950b2ce8246c2c25aff92bb2dc38
https://pubmed.ncbi.nlm.nih.gov/36531846
https://pubmed.ncbi.nlm.nih.gov/36531846
Autor:
Aleksandr Lazaryan, Michelle Dolan, Mei-Jie Zhang, Hai-Lin Wang, Mohamed A. Kharfan-Dabaja, David I. Marks, Nelli Bejanyan, Edward Copelan, Navneet S. Majhail, Edmund K. Waller, Nelson Chao, Tim Prestidge, Taiga Nishihori, Partow Kebriaei, Yoshihiro Inamoto, Betty Hamilton, Shahrukh K. Hashmi, Rammurti T. Kamble, Ulrike Bacher, Gerhard C. Hildebrandt, Patrick J. Stiff, Joseph McGuirk, Ibrahim Aldoss, Amer M. Beitinjaneh, Lori Muffly, Ravi Vij, Richard F. Olsson, Michael Byrne, Kirk R. Schultz, Mahmoud Aljurf, Matthew Seftel, Mary Lynn Savoie, Bipin N. Savani, Leo F. Verdonck, Mitchell S. Cairo, Nasheed Hossain, Vijaya Raj Bhatt, Haydar A. Frangoul, Hisham Abdel-Azim, Monzr Al Malki, Reinhold Munker, David Rizzieri, Nandita Khera, Ryotaro Nakamura, Olle Ringdén, Marjolein van der Poel, Hemant S. Murthy, Hongtao Liu, Shahram Mori, Satiro De Oliveira, Javier Bolaños-Meade, Mahmoud Elsawy, Pere Barba, Sunita Nathan, Biju George, Attaphol Pawarode, Michael Grunwald, Vaibhav Agrawal, Youjin Wang, Amer Assal, Paul Castillo Caro, Yachiyo Kuwatsuka, Sachiko Seo, Celalettin Ustun, Ioannis Politikos, Hillard M. Lazarus, Wael Saber, Brenda M. Sandmaier, Marcos De Lima, Mark Litzow, Veronika Bachanova, Daniel Weisdorf
Publikováno v:
Haematologica, Vol 106, Iss 8 (2021)
Externí odkaz:
https://doaj.org/article/5f4f65fecf5144b8af57be068ff20e60
Autor:
Ibrahim Aldoss, Bijal D. Shah, Jae H. Park, Lori Muffly, Aaron C. Logan, Patrick Brown, Wendy Stock, Elias J. Jabbour
Publikováno v:
American Journal of Hematology. 98:666-680
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90cc201615343ef9000b5f71d8dd820c
https://doi.org/10.1002/ajh.26853
https://doi.org/10.1002/ajh.26853
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:878-882
Measurable residual disease (MRD) is an established component of acute lymphoblastic leukemia (ALL) management in both children and adults. Society guidelines and expert consensus documents include assessment of MRD as the standard of care following
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6d9d0d5e456fdf551b517a8d6eb25f9
https://doi.org/10.1016/j.clml.2022.08.004
https://doi.org/10.1016/j.clml.2022.08.004
Autor:
Aleksandr Lazaryan, Michelle Dolan, Mei-Jie Zhang, Hai-Lin Wang, Mohamed A. Kharfan-Dabaja, David I. Marks, Nelli Bejanyan, Edward Copelan, Navneet S. Majhail, Edmund K. Waller, Nelson Chao, Tim Prestidge, Taiga Nishihori, Partow Kebriaei, Yoshihiro Inamoto, Betty Hamilton, Shahrukh K. Hashmi, Rammurti T. Kamble, Ulrike Bacher, Gerhard C. Hildebrandt, Patrick J. Stiff, Joseph McGuirk, Ibrahim Aldoss, Amer M. Beitinjaneh, Lori Muffly, Ravi Vij, Richard F. Olsson, Michael Byrne, Kirk R. Schultz, Mahmoud Aljurf, Matthew Seftel, Mary Lynn Savoie, Bipin N. Savani, Leo F. Verdonck, Mitchell S. Cairo, Nasheed Hossain, Vijaya Raj Bhatt, Haydar A. Frangoul, Hisham Abdel-Azim, Monzr Al Malki, Reinhold Munker, David Rizzieri, Nandita Khera, Ryotaro Nakamura, Olle Ringdén, Marjolein van der Poel, Hemant S. Murthy, Hongtao Liu, Shahram Mori, Satiro De Oliveira, Javier Bolaños-Meade, Mahmoud Elsawy, Pere Barba, Sunita Nathan, Biju George, Attaphol Pawarode, Michael Grunwald, Vaibhav Agrawal, Youjin Wang, Amer Assal, Paul Castillo Caro, Yachiyo Kuwatsuka, Sachiko Seo, Celalettin Ustun, Ioannis Politikos, Hillard M. Lazarus, Wael Saber, Brenda M. Sandmaier, Marcos De Lima, Mark Litzow, Veronika Bachanova, Daniel Weisdorf, Acute Leukemia Committee of the CIBMTR
Publikováno v:
Haematologica, Vol 105, Iss 5 (2020)
Cytogenetic risk stratification at diagnosis has long been one of the most useful tools to assess prognosis in acute lymphoblastic leukemia (ALL). To examine the prognostic impact of cytogenetic abnormalities on outcomes after allogeneic hematopoieti
Externí odkaz:
https://doaj.org/article/0a9dd539d4d7436794f9d085bd9329f3